timothy sykes logo
BIAF Stock Draws Traders As Federal Deal Fuels Volatility Thumbnail
G Google News

BIAF Stock Draws Traders As Federal Deal Fuels Volatility

TIM SYKES•UPDATED SEP. 1, 2026, 9:19 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

bioAffinity Technologies Inc. stocks have been trading up by 55.51 percent following highly positive coverage of its cancer diagnostics advancements.

Key Takeaways BIAF Traders Need To Know

  • bioAffinity Technologies signed a nationwide federal healthcare distribution agreement with AvMEDICAL for its CyPath Lung test, opening access to VA and other federal healthcare systems.
  • In Q2 2026, bioAffinity Technologies reported CyPath Lung test volume up 216% year over year, with physician accounts rising 122% and existing customers boosting orders 71%.
  • CyPath Lung revenue for the first half of 2026 grew 159% to about $0.8M, helping push total Q2 revenue up 19% year over year to $1.5M.
  • The company remains unprofitable, ended 2026/06/30 with $2.4M in cash despite a $3.2M equity raise, and faces Nasdaq delisting risk tied to ongoing dilution and execution pressure.
  • bioAffinity posted Q2 2026 EPS of -$0.64 versus -$5.07 a year ago on $1.5M revenue, underscoring improving but still negative earnings as CyPath Lung adoption ramps.

Candlestick Chart

Live Update At 09:18:37 EDT: On Tuesday, September 01, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 55.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF is trading like a classic small-cap biotech battleground. The daily chart shows a massive reset: shares sat around $0.40 for much of August, then ripped above $6 on heavy volume, before fading back toward the mid-$4 range. That kind of 10x-type move followed by sharp pullbacks is exactly what momentum traders hunt — and where late chasers get crushed.

Intraday, the 5‑minute data on the spike day shows BIAF exploding from roughly $4.80 at 08:00 to highs above $8.40 within minutes, then chopping between $6.20 and $7.30. This is pure volatility. For short-term trading, that means plenty of opportunity, but also the need for tight risk control.

More Breaking News

Fundamentally, bioAffinity Technologies generated Q2 2026 revenue of $1.5M, with total trailing revenue around $6.2M. Gross margin sits at a healthy 52.6%, but profitability is nowhere in sight. EBITDA for the quarter was about -$3.3M, and net loss was -$3.37M, driving ugly return metrics like return on equity below -300%. BIAF raised cash via equity, leaving about $2.4M on the balance sheet at 2026/06/30. With a price-to-sales ratio under 1 and price-to-book under 1, the market is discounting both the growth story and the risk of more dilution.

Why Traders Are Watching BIAF Right Now

The real catalyst putting BIAF on day-trader screens is the federal distribution deal. bioAffinity Technologies signed a nationwide agreement with AvMEDICAL to distribute its CyPath Lung diagnostic into U.S. government healthcare systems, including the Department of Veterans Affairs. For a tiny commercial-stage company, this is a big validation. It plugs CyPath Lung straight into existing VA procurement channels and a specialized government-facing sales force.

That backdrop helps explain the violent move in BIAF shares. Traders love a clean, simple narrative: small cancer‑diagnostics name lands nationwide VA access, volume explodes, shorts scramble, and liquidity floods in. The intraday spike from the $4s to the $8s lines up with that kind of “headline plus thin float” reaction.

Under the hood, the core business is actually showing real momentum. In Q2 2026, CyPath Lung test volume jumped 216% year over year. Physician accounts grew 122%, and existing customers ordered 71% more tests. For the first half of 2026, CyPath Lung revenue rose 159% to about $0.8M, helping power that $1.5M Q2 revenue print. BIAF is also advancing a VA‑ and military‑backed longitudinal clinical trial, while building a broader pipeline in asthma/COPD diagnostics and siRNA-based skin cancer therapeutics.

But this is not a clean growth story. bioAffinity Technologies is still burning a lot of cash. Q2 operating cash flow was roughly -$3.2M, and free cash flow about -$3.3M. Even after a $3.2M equity raise, BIAF ended 2026/06/30 with only about $2.4M in cash. Management has also flagged Nasdaq delisting risk, which usually means reverse splits, more raises, or both. For traders, that combination — real revenue growth plus balance‑sheet stress — often translates into recurring spikes around news and offerings.

Conclusion

BIAF sits in that dangerous but tradable zone where strong operational progress collides with weak financials. On one side, bioAffinity Technologies is posting serious growth in its CyPath Lung business, with test volumes, physician adoption, and revenue all climbing fast from a small base. EPS improved to -$0.64 from -$5.07 year over year, a huge step up even if the company still loses money. The new AvMEDICAL deal could expand CyPath Lung access across VA and other federal systems, giving BIAF a clearer commercial path than many micro‑cap biotechs ever see.

On the other side, the numbers scream risk. Net losses remain large, free cash flow is deeply negative, and cash on hand is limited. Nasdaq delisting risk hangs over the tape, which usually means ongoing dilution for anyone holding through the noise. That’s why traders should treat BIAF as a trading vehicle, not a comfortable long-term hold.

In the Tim Sykes world, this is exactly the kind of chart you study, not marry. As Tim says, “Volatile stocks are the best teachers — if you respect risk, study the catalysts, and never forget to cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. For active traders, BIAF is a live case study in how real fundamentals, headline catalysts, and structural risk combine to create momentum — and why discipline matters more than any single story.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”